Combined use of Campath and total skin electron beam irradiation in mycosis fungoides
https://doi.org/10.17650/1818-8346-2007-0-1-42-47
Abstract
This article demonstrates case report and review of literature of successful use Campath in combination with total skin electron beam irradiation in mycosis fungoides.
About the Authors
V. A. Doronin
Central Railway Clinical Hospital №2 named N.A. Semashko
Russian Federation
Russian Federation
Y. A. Krivolapov
Regional bureau of pathology Saint-Peterburg
Russian Federation
Russian Federation
A. V. Nechesnyuk
Central Railway Clinical Hospital №2 named N.A. Semashko
Russian Federation
Russian Federation
A. V. Pivnik
Russian Medical Postgraduate Academy
Russian Federation
Russian Federation
Department of hematology and intensive care
References
1. Willemze R., Jaffe E.S., Burg G. et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768—85.
2. Kim Y.H., Lin H.L., Mrar-Gernhard S. et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139(7):857—66.
3. Massone C., Kodama K., Kerl H., Cerroni L. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 2005; 29: 550—60.
4. Pimpinelli N., Olsen E.A., Santucci M. et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005;53:1053—63.
5. Nickoloff B.J. Light-microscopic assessment of 100 patients with patch/plaque-stage mycosis fungoides. Am J Dermatopathol 1988;10:469—77.
6. Ralfkiaer E. Controversies and discussion on early diagnosis of cutaneous T-cell lymphoma. Phenotyping Dermatol Clin 1994;12:329—34.
7. Karenko L., Hyytinen E., Sarna S., Ranki A. Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods. J Invest Dermatol 1997;108:22—9.
8. Smoller B.R., Santucci M., Wood G.S., Whittaker S.J. Histopathology and genetics of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003;17:1277—311.
9. Bunn P.A., Lamberg S.I. Report of the Committee on Staging and Classification of Cutaneous T-cell Lymphomas. Cancer Treat Rep 1979;63(4):725—8.
10. Gilchrest B.A., Parrish J.A., Tanenbaum L. et al. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976;38:683—98.
11. Roenigk H.H. Photochemotherapy for mycosis fungoides: long-term follow-up study. Cancer Treat Rep 1979;63:669—73.
12. Roupe G., Sandstro m M.H., Kjellstrom C. PUVA in early mycosis fungoides may give long-term remission and delay extracutaneous spread. Acta Dermatol Venereol (Stockh) 1996;76:475—8.
13. Kuzel T.M., Roenigk H.H., Samuelson E. et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 1995;13:257—63.
14. Rupoli S., Barolli S., Guiducci B. et al. Low dose interferon-a 2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Haematologica 1999;84:809—13.
15. Stadler R., Otte H.-G., Kohl H.P. et al. Prospective randomized multicenter clinical trial on the use of interferon-a 2a plus acitretin versus interferon-a 2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998;92:3578—81.
16. Kaye FJ., Bunn P.A., Steinberg S.M. et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784—90.
17. Edelson R., Berger C., Gasparro F. et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med 1987;316:297—303.
18. Evans A.V., Wood B.P., Scarisbrick J.J. et al. Extracorporeal photopheresis in Sezary syndrome: hematologic parameters as predictors of response. Blood 2001;98:1298—301.
19. Micialy B., Miyamoto C., Kantor G. et al. Radiotherapy for unilesional mycosis fungoides. Intern J Radiat Oncol Biol Phys 1998;42:361—4.
20. Rosenblatt E., Kuten A., Leviov M., Cederbaum M. Total skin electron irradiation in mycosis fungoides: dose and fractionation considerations. Leuk Lymphoma 1998;30:143—51.
21. Akpek G., Koh H.K., Bogen S. et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999;86:1368—76.
22. Bunn P.A., Hoffman S.J., Norris D. et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994;121:592—602.
23. Kurzrock R., Pilat S., Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999;17:3117—21.
24. Kuzel T.M., Hurria A., Samuelsson E. et al. Phase II trial of 2-chlorodeoxyadino-sine for the treatment of cutaneous T-cell lymphoma. Blood 1996;87:906—11.
25. Zackheim H.S., Kashani-Sabet M., Hwang S.T. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996;34:626—31.
26. vanderSpek J.C., Mindell J.A., Finkelstein A., Murphy J.R. Structure/function analysis of the transmembrane domain of DAB389-inter-leukin-2, an interleukin-2 receptor-targeted fusion toxin. The amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic domain to the cytosol of target cells. J Biol Chem 1993;268:12077—82.
27. Dyer M.J., Hale G., Hayhoe F.G., Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431—9.
28. Greenwood J., Clark M., Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993;23:1098—104.
29. Heit W., Bunjes D., Wiesneth M. et al. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 1986;64:479—86.
30. Reichmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1998;332:323—7.
31. Rowan W., Tite J., Topley P., Brett S.J. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998;95:427—36.
32. Ginaldi L., De Martinis M., Matutes E. et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to CAMPATH-1H. Leuk Res 1998;22:185—92.
33. Hale G., Dyer M.J.S., Clark M.R. et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988;2:1394—9.
34. Dearden C.E., Matutes E., Cazin B. et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98:1721—6.
35. Lundin J., Hagberg H., Repp R. et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267—72.
Review
For citations:
Doronin V.A., Krivolapov Y.A., Nechesnyuk A.V., Pivnik A.V. Combined use of Campath and total skin electron beam irradiation in mycosis fungoides. Oncohematology. 2007;(1):42-47. (In Russ.) https://doi.org/10.17650/1818-8346-2007-0-1-42-47
Views:
161
Email this article 